Bethesda, MD-A new study suggests that, even though there is growing evidence that genetic factors impacting hormonal regulation of aggressive prostate cancer are more frequent among African-Americans than other ethnic groups, differences in disease-free survival can be eliminated.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.